Axsome Therapeutics Inc
$ 212.74
1.24%
07 Aug - close price
- Market Cap 10,947,551,000 USD
- Current Price $ 212.74
- High / Low $ 214.39 / 208.61
- Stock P/E N/A
- Book Value 1.06
- EPS -3.77
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -3.49 %
- 52 Week High 260.19
- 52 Week Low 102.67
About
Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$282.32
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-02-23 | 2025-11-03 | 2025-08-04 | 2025-05-05 | 2025-02-18 | 2024-11-12 | 2024-08-05 | 2024-05-06 | 2024-02-20 | 2023-11-06 | 2023-08-07 |
| Reported EPS | -1.26 | -0.56 | -0.94 | -0.97 | -1.22 | -1.54 | -1.3419 | -1.67 | -1.44 | -2.08 | -1.32 | -1.54 |
| Estimated EPS | -0.86 | -0.7256 | -0.9 | -1.09 | -1.35 | -1.0026 | -1.41 | -1.33 | -1.22 | -1.17 | -1.19 | -1.2 |
| Surprise | -0.4 | 0.1656 | -0.04 | 0.12 | 0.13 | -0.5374 | 0.0681 | -0.34 | -0.22 | -0.91 | -0.13 | -0.34 |
| Surprise Percentage | -46.5116% | 22.8225% | -4.4444% | 11.0092% | 9.6296% | -53.6006% | 4.8298% | -25.5639% | -18.0328% | -77.7778% | -10.9244% | -28.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.99 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AXSM
2026-08-08 07:41:47
Assenagon Asset Management S.A. significantly reduced its stake in Axsome Therapeutics, Inc. by 47.5% in the second quarter, selling over 411,000 shares but still retaining a substantial holding valued at $111.3 million. Despite this, institutional investors collectively own 81.49% of the company, and analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $265.55. Insider selling activity was also noted, with two directors recently decreasing their holdings.
2026-08-08 07:41:46
Bank of America Corp DE reduced its stake in Axsome Therapeutics by 3.2% in the first quarter, selling 19,942 shares and retaining 598,091 shares worth $101.1 million. Despite mixed analyst ratings, the company holds a "Moderate Buy" consensus with a $265.55 price target. Over the last three months, company insiders sold 200,766 shares valued at $46.7 million, primarily to cover tax obligations from equity awards.
2026-08-07 23:41:46
Axsome Therapeutics CEO Herriot Tabuteau sold approximately $10.5 million worth of common stock on August 5 and 6, 2026, following the exercise of stock options that were nearing their expiration date. These transactions were executed under a pre-approved 10b5-1 trading plan. Despite the sales, Tabuteau retains a significant indirect beneficial ownership in the company, which has seen a 103% gain over the past year and recently had its New Drug Application for AXS-12 accepted by the FDA.
2026-08-07 03:40:14
Axsome Therapeutics (AXSM) stock appears to be priced near its fair value, despite its premium sales pricing, following a significant 5-year gain and a recent pullback. The company's P/S ratio of 15.3x is higher than industry averages but aligns closely with its estimated fair P/S ratio of 16.6x. The valuation now presents a balanced risk-reward profile, with future performance dependent on the company's ability to convert its pipeline into consistent, high-quality cash flow.
2026-08-06 20:40:14
A holder of Axsome Therapeutics (AXSM) has filed a Form 144 to sell 4,660 common shares through a cashless option exercise, valued at approximately $979,205.80. These shares, acquired in 2017 as compensation via stock options, are intended for sale on or after August 6, 2026. The filing also details several prior sales by Herriot Tabuteau in the preceding three months, ranging from $4.26 million to $6.02 million.
2026-08-05 21:46:12
Axsome Therapeutics insider Herriot Tabuteau has filed a Form 144 indicating an intention to sell up to 45,004 shares of common stock through Goldman Sachs & Co. LLC, with an approximate sale date of August 5, 2026. The shares were originally acquired as compensation via stock options on March 15, 2017, and the transaction is structured as a cashless exercise/same-day sale. This filing also notes previous sales by Tabuteau in June and July 2026, and provides context with the total shares outstanding for Axsome Therapeutics (AXSM).
